

Washington State Health Care Authority


Health Technology Assessment Spine Fusion and Discography


Clinical Committee Meeting November 16, 2007

Contributors and Participants Richard N. Wohns, MD, AANS/CNS, Tacoma, WA Jens R. Chapman, MD, AAOS, University of Washington, Seattle, WA Ray M. Baker, MD, NASS, University of Washington, Seattle, WA Theodore A. Wagner, MD, AAOS, University of Washington, Seattle, WA Paul C. McCormick, MD, Past Chair, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, Columbia University, New York, NY Daniel K. Resnick, MD, Chair-Elect, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, University of Wisconsin, Madison, WI Andrew T. Dailey, MD, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, University of Utah, Salt Lake City, UT Joseph T. Alexander, MD, Chair, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, Scarborough, ME American Academy of Orthopaedic Surgeons[®] North American Spine Society American Association of Neurological HAOS OF URINGRADIC AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS®













- Heterogeneous- cause, structural basis, natural hx, clinical aspects and patient effects, patient's treatment preference and response
- Many patients do well with nonoperative care, some don't.
- Many patients do well with surgery, some don't.
- Wide variation in magnitude of Rx. Effect reflected in SD of outcomes in European RCTs.
- Which treatment is better is not the question.
- Which treatment strategy is likely to have the best probability of providing the greatest benefit to each individual patient.






- Surgery and nonoperative management are not competitive treatments
- Surgery only considered in select patients following a failure to improve with nonoperative treatment.
- Surgery and nonoperative management have different mechanisms of action and are applied under different circumstances
- Complementary treatments utilized in series not in parallel.




4 European based RCTs

- Dichotomous hypothesis based on flawed assumptions
- Unclear inclusion/exclusion criteria
- Eligible patients who refused randomization
- Variability in treatments
- Limited assessment of operative objective
- Crossovers without 'as treated' analysis
- Underpowered (Brox et. al.-2)
- Unavailable control treatment in the USA in ³/₄ trials






- Fairbank Study:
 - Diagnostic criteria poorly described
 - Surgical intervention all over map
 - Many patients not fused
 - Intent to treat analysis with 30% crossover to surgery
 - Significant loss of power due to 25% lost to follow-up in surgical group



Surgical Results from European Studies

Study	ODI	SF-36 PCS/GFS	Pain
Fairbank, 2006	12.5 (SD-21.1)	15 (PCS)	19.5 (SF-36) (SD-26.4)
Brox, 2003	15.6 (SD-16.4)	NA	20.7 (VAS) (SD-27.3)
Fritzell, 2001	11.6 (SD-18)	15 (GFS)	21 (VAS) (SD-25.2)




A Prospective, Randomized, Multicenter Food and Drug Administration Investigational Device Exemptions Study of Lumbar Total Disc Replacement With the CHARITÉTM Artificial Disc Versus</sup> Lumbar Fusion

Part I: Evaluation of Clinical Outcomes








ECRI and Intensive Multidisciplinary Nonoperative Management

- ECRI review implies that regimens similar to Brox regimen exist in Washington State (page 39 reference 114)
- Treatment at multidisciplinary centers has not been associated with improved outcomes (notably in Washington State)

Outcomes of Pain Center Treatment in Washington State Workers' Compensation

James P. Robinson, MD, PhD,¹ Deborah Fulton-Kehoe, MPH,² Donald C. Martin, PhD,³ and Gary M. Franklin, MD, MPH^{2,4}

Results Univariate analysis revealed that at 2-year follow-up, 35% of treated subjects were receiving time loss payments vs. 40% of evaluated only subjects (P < 0.05). Subjects who were younger, female, and less chronic were more likely to undergo pain center treatment and were less likely to be on time loss at 2-year follow-up. In multivariate analyses, which statistically controlled baseline differences between the two groups, there was no difference between treated subjects and evaluated only subjects. **Conclusions** There was no evidence that pain center treatment alters 2-year time loss status of already disabled workers. Am. J. Ind. Med. 39:227–236, 2001.





ECRI estimation of "true impact of surgery"

We consider the estimates in this study to be the best empirical estimates of clinically important change in ODI and VAS. Although the pre-post change in ODI is technically a different concept than the between-group difference in ODI, we consider the two concepts similar enough that the pre-post change can be used as a surrogate for the between-group difference. We view the control group as a surrogate for the active-treatment group: what change would the surgical patients have experienced if they had received non-surgical treatment? Taking this view, the between-group difference at followup is therefore an unbiased estimate of the surgical group's change score *after factoring out the non-surgical treatment effect*. Thus, our use of 10 units on Oswestry is, technically speaking, the change score at which the *true impact of surgery* is considered clinically significant. Accordingly, we used a difference of 10 for the ODI and a difference of 20 for the VAS as the minimal clinically important difference in our assessment of these outcomes.


Mean surgery outcome- mean nonoperative outcome= "true impact of surgery"

p. 27












- If fusion is not performed, what alternatives exist for patients with disabling low back pain?
- ECRI analysis showed no benefit of either intensive cognitive or unstructured PT that reached MCID in any RCT or meta-analysis (Brox/Fairbank)




Conclusion


 No effective alternative treatment modality exists for these patients in the United States, including Washington State.






















- DDD in association with chronic low back pain that has not responded to conservative therapy is considered by many surgeons as an indication for spinal fusion
- Goal is to permanently immobilize the spinal column vertebrae surrounding the disc(s) that is(are) diagnosed as the cause of chronic low back pain


Institute































S	tudies and N		0	Spinal ve The		n
	Study	Country	Design	No. of patients randomized	Followup	
	Brox et al. 2006	Norway	RCT	60	1 year	A
	Fairbank et al. 2005	UK	RCT	349	2 years	
	Brox et al. 2003	Norway	RCT	64	1 year	
	Fritzell et al. 2001	Sweden	RCT	294	2 years	
21 of 6	9 11/16/2007				RIIn of Science. The Integ	









Generalizability


- Fusion strategies: different surgical approaches and instrumentation used in different studies
- Patients: Average age 40-45 years, but other characteristics differed among studies. One study excluded patients with prior back surgery, one study included only patients with prior back surgery, remaining studies included mostly patients without prior back surgery. One study had 11% patients with spondylolisthesis.


Institute







































- All trials calculated adverse event rates on a per protocol basis (only patients who actually received surgery were included in calculations)
- No adverse events reported in non-operative control groups in any of these trials
- Most early and late events reported in surgical groups could not have occurred in the absence of surgery


Institute


The Discipline of Science. The Integrity of Independence




Adverse event	No. of studies reporting event	Range of reported event rates	
Reoperation	18/27 (1 reported 0 events)	0% to 46.1%	
nfection (deep or superficial)	14/27 (1 reported 0 events)	0% to 9%	
Veurologic	12/27 (no study reported 0 events)	0.7% to 25.8%	
Bleeding/ vascular injury	10/27 (2 reported 0 events)	0% to 12.8%	
Thrombosis	11/27 (1 reported 0 events)	0% to 4%	
Dural injury	10/27 (no study reported 0 events)	0.5% to 29%	
Hematoma	7/27 (no study reported 0 events)	1% to 4%	
Retrograde ejaculation	6/27 (no study reported 0 events)	0.7% to 6%	
Device-related	13/27 (1 reported 0 events with a specific type of fusion)	0% to 17.8%	
Death	4/27 (the other 22 studies were assumed to have 0 surgically-related deaths)	0% to 2%	






































Test-Retest Reliability Data							
		Test-retest kappa (95% CI)					
Study	Discs	Rater 1	Rater 2	Rater 3			
Agora-	133	0.80	0.85	0.80			
stides		(0.71 to 0.89)	(0.77 to 0.93)	(0.70 to 0.90)			
(2002)							
Not enough data to permit a conclusion							
ECRI Institute							
55 of 69 11/16/2007 The Discipline of Science. The Integrity of Independence.							


Study	Discs	System	Kappa (95% CI)
Agorastides	133	Adams	0.77
(2002)		classification	(0.66 to 0.87)
Milette (1999)	132	DDD	0.67
, , , , , , , , , , , , , , , , , , ,		degeneration	(0.55 to 0.78)
Milette (1999)	132	DDD disruption	0.66
((0.56 to 0.76)
		DDD disruption	(0.56 to 0.7
























Washington State Health Care Authority


Health Technology Assessment Spine Fusion and Discography


Clinical Committee Meeting November 16, 2007

Contributors and Participants Richard N. Wohns, MD, AANS/CNS, Tacoma, WA Jens R. Chapman, MD, AAOS, University of Washington, Seattle, WA Ray M. Baker, MD, NASS, University of Washington, Seattle, WA Theodore A. Wagner, MD, AAOS, University of Washington, Seattle, WA Paul C. McCormick, MD, Past Chair, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, Columbia University, New York, NY Daniel K. Resnick, MD, Chair-Elect, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, University of Wisconsin, Madison, WI Andrew T. Dailey, MD, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, University of Utah, Salt Lake City, UT Joseph T. Alexander, MD, Chair, AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, Scarborough, ME American Academy of Orthopaedic Surgeons[®] North American Spine Society American Association of Neurological HAOS OF URINGRADIC AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS®













- Heterogeneous- cause, structural basis, natural hx, clinical aspects and patient effects, patient's treatment preference and response
- Many patients do well with nonoperative care, some don't.
- Many patients do well with surgery, some don't.
- Wide variation in magnitude of Rx. Effect reflected in SD of outcomes in European RCTs.
- Which treatment is better is not the question.
- Which treatment strategy is likely to have the best probability of providing the greatest benefit to each individual patient.






- Surgery and nonoperative management are not competitive treatments
- Surgery only considered in select patients following a failure to improve with nonoperative treatment.
- Surgery and nonoperative management have different mechanisms of action and are applied under different circumstances
- Complementary treatments utilized in series not in parallel.




4 European based RCTs

- Dichotomous hypothesis based on flawed assumptions
- Unclear inclusion/exclusion criteria
- Eligible patients who refused randomization
- Variability in treatments
- Limited assessment of operative objective
- Crossovers without 'as treated' analysis
- Underpowered (Brox et. al.-2)
- Unavailable control treatment in the USA in ³/₄ trials






- Fairbank Study:
 - Diagnostic criteria poorly described
 - Surgical intervention all over map
 - Many patients not fused
 - Intent to treat analysis with 30% crossover to surgery
 - Significant loss of power due to 25% lost to follow-up in surgical group



Surgical Results from European Studies

Study	ODI	SF-36 PCS/GFS	Pain
Fairbank, 2006	12.5 (SD-21.1)	15 (PCS)	19.5 (SF-36) (SD-26.4)
Brox, 2003	15.6 (SD-16.4)	NA	20.7 (VAS) (SD-27.3)
Fritzell, 2001	11.6 (SD-18)	15 (GFS)	21 (VAS) (SD-25.2)




A Prospective, Randomized, Multicenter Food and Drug Administration Investigational Device Exemptions Study of Lumbar Total Disc Replacement With the CHARITÉTM Artificial Disc Versus</sup> Lumbar Fusion

Part I: Evaluation of Clinical Outcomes








ECRI and Intensive Multidisciplinary Nonoperative Management

- ECRI review implies that regimens similar to Brox regimen exist in Washington State (page 39 reference 114)
- Treatment at multidisciplinary centers has not been associated with improved outcomes (notably in Washington State)

Outcomes of Pain Center Treatment in Washington State Workers' Compensation

James P. Robinson, MD, PhD,¹ Deborah Fulton-Kehoe, MPH,² Donald C. Martin, PhD,³ and Gary M. Franklin, MD, MPH^{2,4}

Results Univariate analysis revealed that at 2-year follow-up, 35% of treated subjects were receiving time loss payments vs. 40% of evaluated only subjects (P < 0.05). Subjects who were younger, female, and less chronic were more likely to undergo pain center treatment and were less likely to be on time loss at 2-year follow-up. In multivariate analyses, which statistically controlled baseline differences between the two groups, there was no difference between treated subjects and evaluated only subjects. **Conclusions** There was no evidence that pain center treatment alters 2-year time loss status of already disabled workers. Am. J. Ind. Med. 39:227–236, 2001.





ECRI estimation of "true impact of surgery"

We consider the estimates in this study to be the best empirical estimates of clinically important change in ODI and VAS. Although the pre-post change in ODI is technically a different concept than the between-group difference in ODI, we consider the two concepts similar enough that the pre-post change can be used as a surrogate for the between-group difference. We view the control group as a surrogate for the active-treatment group: what change would the surgical patients have experienced if they had received non-surgical treatment? Taking this view, the between-group difference at followup is therefore an unbiased estimate of the surgical group's change score *after factoring out the non-surgical treatment effect*. Thus, our use of 10 units on Oswestry is, technically speaking, the change score at which the *true impact of surgery* is considered clinically significant. Accordingly, we used a difference of 10 for the ODI and a difference of 20 for the VAS as the minimal clinically important difference in our assessment of these outcomes.


Mean surgery outcome- mean nonoperative outcome= "true impact of surgery"

p. 27














- If fusion is not performed, what alternatives exist for patients with disabling low back pain?
- ECRI analysis showed no benefit of either intensive cognitive or unstructured PT that reached MCID in any RCT or meta-analysis (Brox/Fairbank)



Conclusion

 No effective alternative treatment modality exists for these patients in the United States, including Washington State.








3



- The HTA is probably not the optimal process for achieving better health for our patients.
- Evidence Based Medicine (EBM)
 - 3 components
 - Relationship to LBP and Spine Fusion
 - Critical Appraisal and Surgical Trials
- A proposal for an improved process for achieving better health for our patients.







7


Components of EBM


1. Best available evidence, 2. Clinical Expertise


3. Patient Preference


Question/s


- 1. Does lumbar fusion surgery reduce pain and improve function more effectively then non surgical treatments for DDD?
- 2. Rates of Adverse Events?
- 3. Patient Characteristics that are associated with 1 and 2?
- What about the disease and intervention?
















Recent Examples		
The 2	IEW ENGLAND JOURNAL of MEDICINE	
	ORIGINAL ARTICLE	
for Lumba James N. Wein Brett Hanscom, Nancy J.O. Birkmey Frank P. Cammisa, I Lawrence G. Lenl	versus Nonsurgical Treatment r Degenerative Spondylolisthesis tein, D.O., Jon D. Lurie, M.D., Tor D. Tosteson, Sc.D., M.S., Anna N.A. Tosteson, Sc.D., Emily A. Blood, M.S., er, Ph.D., Alan S. Hilbrand, M.D., Harry Herkowitz, M.D., d.D., Todd J. Albert, M.D., Sanford E. Emery, M.D., M.B.A., e, M.D., William A. Abdu, M.D., Michael Longley, M.D., tas J. Errico, M.D., and Serena S. Hu, M.D.*	N Engl J Med 2007;356:2257-70.
for Lumbar D	Context Lumbar diskectorny is the most common surgical procedure performed for back and leg symptoms in US patients, but the efficacy of the procedure relative to nonoperative care remains controversial. Objective To assess the efficacy of surgery for lumbar intervertedad disk hemiation. Design, Setting, and Patients The Signe Patient Outcome Research Trial, a nan-	JAMA 2007
william A. Abdu, MD William A. Abdu, MD, MS Man S. Hilibrand, MD Scott D. Boden, MD Richard A. Deyo, MD, MPH	domized chinal fial enrolling patients between March 2000 and November 2004 from 13 multidealphary sprine efficies: 11 US states. Patient verse 701 supplies and dates the state of the state of the hernitation and persistent signs and symptoms of radiculopathy for at least 6 weeks. Interventions: Standard open diskectomy vs nonoperative treatment individualized to the patient. Main Outcome Measures Pinnaro outcomes were channels from baseline for the Main Outcome Measures Pinnaro outcomes were channels from baseline for the	13














WA Health Technology Assessment Lumbar Fusion and Discography Review November 16, 2006


> Paul Schwaegler, MD Orthopedics International Seattle, WA







> Weinstein, JN et al. - Spine, 31 (23):2707-2714 2006

- 1992-2003 Rates of discectomy and fusion have increased in Medicare Patients, as well as regional variations – why??
- Caveats <u>Based on Claims data, inability to determine primary</u> diagnosis/indications, number of disabled patients or comorbidity status, number of revision patients included, which fusion tx works best, or per capita spine surgeon availability in U.S....that being said....
 - Access to better technology and tx
 - Excellent outcomes (function, pain relief, RTW, satisfaction, low complications, etc.) Supported by recent SPORT data - Weinstein 2007, and Fritzell 2002, Burkus 2003, Glassman 2006, Schwender 2005, etc.
 - More treatment options than 15 yrs ago biologics, fusion, open, MIS, etc.
 - Relatively short pt. wait time and surgery access following failure of conservative care
 → best outcomes (Braybooke 2007)
 - Better informed (internet) and more aggressive patients unwilling to live in pain and longer life spans
 - Willingness to travel (regional variation may be due to patients traveling further to see a specialist) – we even have patients leave the US for other countries to obtain surgery









Washington Patients – Workers Compensation vs. Other Payors


- Restrictive state WC guidelines create a second rate of care for injured workers
- Wait time is exorbitant for WC patients needing lumbar fusion vs. other WA patients
- > HTA should be cautious when considering taking decisions away from WA spine surgeons that could delay patient care






	nancial Conflict Disclosu				nat
Di	rect or indirect remuneration	None ¹	Minor ²		Company/Companies
a.	Royalties			X	U <u>W Tech Transfer (Synth</u> es)
b.	Stock ownership (options, warrants)	X			
c.	Consulting fees	X			0
d.	Loans from the sponsor	X			
e.	Speaking arrangements	X			
Ho	lding a position in a company	4			
f.	Board of Directors	X			
g.	Scientific Advisory Board	X			
h.	Other office in the company	X			
Re	ceiving support from sponsors				Depuy, Surgical Dynamics, Synthes
i.	Endowments ⁵			X	(to UW Dept. of Orthopedics)
j.	Equipment				· · · · · · · · · · · · · · · · · · ·
k.	Biomaterials	X			· · · · · · · · · · · · · · · · · · ·
1.	Discretionary funds	X			
m.	Support of staff or training6			X D	epuy, Synthes (to Dept of Orthop)
n.	Trips	X			
о.	Other sponsorship	X			







Treatment Options for Discogenic Pain


- · Observation, rehabilitation, pain management
- Intradiscal electrothermal coagulation (IDET)
- · Posterolateral in situ fusion (no hardware)
- Instrumented posterior fusion (pedicle screws)
- Anterior lumbar interbody fusion (ALIF)
- · Laparoscopic / Minimally Invasive fusion
- Posterior lumbar interbody fusion (PLIF)
- Combined anterior and posterior (360°) fusion
- Artificial Disc Replacement








Geographical	/ariations in	Spine Surgery Rates				
	(rate per 1,000 enrollees within the 2001 U.S. Medicare population)					
Low-rate states		High-rate states	,			
Hawaii	1.8	Montana	7.4			
Vermont	2.6	Oregon	7.5			
New Jersey	2.7	Idaho	8.4			
New York	2.7	Wyoming	9.2			
Low-rate cities		High-rate cities				
Terre Haute, IN	1.6	Ft. Collins, CO	8.0			
Bronx, NY	1.7	Eugene, OR	8.0			
Honolulu, HI	1.8	Idaho Falls, ID	8.2			
Wilkes-Barre, PA	2.0	Slidell, LA	8.2			
Manhattan, NY	2.1	Amarillo, TX	8.3			
McAllen, TX	2.1	Newport News, VA	8.3			
Huntington, WV	2.2	Billings, MT	8.4			
Hackensack, NJ	2.2	Greeley, CO	8.6			
Lebanon, NH	2.3	Rapid City, SD	8.6			
Newark, NJ	2.3	Casper, WY	9.5			
East Long Island, NY	2.3	Boise, ID	9.9			
Paterson, NJ	2.4	Bend, OR	10.2			
Deyo, Mirza CORR 2006	Overall	U.S. Rate 4.5				

































RCT: fusion vs. non-op results


Final follow-up interval Follow-up rate			Fairbanl 2 years 82%	k <u>Brox 06</u> 1 year 97%
<u>Surgery Group</u>	n=201	n=35	n= 176	n=29
Baseline Oswestry Index	47	42	46	47
Final Oswestry Index	<u>35</u>	<u>26</u>	<u>34</u>	<u>38</u>
Change(Final – Baseline)	-12	-16	-12	-9
Percent Improvement	24%	37%	27%	19%
<u>Nonoperative Group</u>	n=63	n=26	n= 173	n=31
Baseline Oswestry Index	48	43	45	45
Final Oswestry Index	<u>45</u>	<u>30</u>	<u>36</u>	<u>32</u>
Change(Final – Baseline)	-3	-13	-9	-13
Percent Improvement	6%	30%	12%	28%
Mirza, Deyo Spine 2007				


Final follow-up interval Follow-up rate		1 year	<u>3 Fairban</u> 2 years 82%	•
Differential improvement across treatments (∆Surg – ∆Nonop)		0770	0270	0170
Change in Oswestry Index	8.8	2.3	3.8	(-3.9)
Percent benefit with surgery	19%	7.0%	8%	(-10%)


Г













		Ν	Iultivariate Anal	ysis
Outcomes OR (95% Cl)	Neither (Reference)	Cage alone	Instrumentation alone	Both
Work disability	1	1.46 0.98-2.16	1.07 0.78-1.47	1.07 0.72-1.57
Postoperative complications		1.98* 1.02-3.80	1.86* 1.07-3.22	2.20* 1.16-4.16
Reoperation	1	0.82 0.53-1.27		0.80 0.50-1.26





Number of Studies Reporting	Specified Comp	lications by Sur	gical Apploac
Complication	Anterior	Posterior	Total
	<u>n (%)</u>	<u>n (%)</u>	<u>n (%)</u>
Non-union	15 (83)*	10 (100)	23 (85)
Reoperation	14 (74)^	7 (70)	20 (74)
Major Vessel Injury	12 (55)	1 (10)	12 (40)
Retrograde Ejaculation	12 (55)	1 (10)	12 (40)
Visceral Injury	3 (14)	0	3 (10)
Transfusion	3 (14)	1 (10)	4 (14)
Neurologic Complication	4 (18)	6 (60)	10 (33)
Dural Injury	2 (9)	7 (70)	8 (27)
Infection	3 (14)	5 (50)	8 (27)
	(N=22 studies)	(N=10 studies)	(N=30 studies




Potential Financial Conflicts of Interest


Favorable Results in Industry-Sponsored Research


<u>Sponsor</u>	<u>Odds Ratio</u>	<u>95% CI</u>
Sponsor of study	3.6	2.6 to 4.9
For-profit organizations	5.3	2.0 to 14.4
Manufacturer of drugs	8.0	1.1 to 53.2
Spinal device manufact	turer 3.3	2.4 to 4.5

Jacobs, Galante, Mirza, Zdeblick JBJS 2006

<u>Favora</u>	ble Results	
Field	Industry-funded	Independent
Spine	73	44
Hip	93	37
Knee	75	20
Jacobs, Galante, Mirza, Zdeb	lick JBJS 2006	







HTCC Coverage and Reimbursement Determination Analytic Tool

HTA's goal is to achieve *better health care outcomes* for enrollees and beneficiaries of state programs by paying for proven health *technologies that work*.

To find best outcomes and value for the state and the patient, the HTA program focuses on these questions:

- 1. Is it safe and effective?
- 2. Is it more effective or safer?
- 3. Is it equally effective and safe, and more cost-effective?

The principles HTCC uses to review evidence and make determinations are:

Principle One: Determinations are Evidence based

HTCC requires scientific evidence that a health technology is safe, effective and cost-effective¹ as expressed by the following standards.²

- Persons will experience better health outcomes than if the health technology was not covered and that the benefits outweigh the harms.
- The HTCC emphasizes evidence that directly links the technology with health outcomes. Indirect evidence may be sufficient if it supports the principal links in the analytic framework.
- Although the HTCC acknowledges that subjective judgments do enter into the evaluation of evidence and the weighing of benefits and harms, its recommendations are not based largely on opinion.
- The HTCC is explicit about the scientific evidence relied upon for its determinations.

Principle Two: Determinations result in health benefit

The outcomes critical to HTCC in making coverage and reimbursement determinations are health benefits and harms.³

- In considering potential benefits, the HTCC focuses on absolute reductions in the risk of outcomes that people can feel or care about.
- In considering potential harms, the HTCC examines harms of all types, including physical, psychological, and non-medical harms that may occur sooner or later as a result of the use of the technology.
- Where possible, the HTCC considers the feasibility of future widespread implementation of the technology in making recommendations.
- The HTCC generally takes a population perspective in weighing the magnitude of benefits against the magnitude of harms. In some situations, it may make a determination for a technology with a large potential benefit for a small proportion of the population.
- In assessing net benefits, the HTCC subjectively estimates the indicated population's value for each benefit and harm. When the HTCC judges that the balance of benefits and harms is likely to vary substantially within the population, coverage or reimbursement determinations may be more selective based on the variation.
- The HTCC considers the economic costs of the health technology in making determinations, but costs are the lowest priority.

¹ Based on Legislative mandate: See RCW 70.14.100(2).

² The principles and standards are based on USPSTF Principles at: http://www.ahrq.gov/clinic/ajpmsuppl/harris3.htm

³ The principles and standards are based on USPSTF Principles at: http://www.ahrq.gov/clinic/ajpmsuppl/harris3.htm

HTCC Evaluation Factors

HTCC implements the program mandate and key principles that the decision be evidence based and that it be weighted most importantly on whether a given technology is safe and improves health through a decision tool.

Using Evidence as the basis for a Coverage Decision

Evaluate the primary coverage question by identifying for each primary factor (Safety, Effectiveness, and Cost) whether (1) evidence is available, (2) the confidence in the evidence, and (3) applicability to decision.

1. Availability of Evidence:

Committee members decide whether information is available - Yes/No

2. Confidence in the Evidence:

Committee members decide how confident they are in the scientific evidence by identifying the type and quality of evidence⁴ for consideration such as:

- Type of evidence as reported in the technology assessment or other evidence presented to committee (randomized trials, observational studies, case series, expert opinion);
- the amount of evidence (sparse to many number of evidence or events or individuals studied);
- consistency of evidence (results vary or largely similar);
- recency (timeliness of information);
- directness of evidence (link between technology and outcome);
- relevance of evidence (applicability to agency program and clients);
- bias (likelihood of conflict of interest or lack of safeguards).

Not Confident	Confident
Appreciable uncertainty exists. Further	Very certain of evidentiary support.
information is needed or further	Further information is unlikely to change
information is likely to change confidence.	confidence

3. Factors for Consideration - Importance

Committee members also consider the degree of importance that particular evidentiary information has to the policy and coverage decision. Factors used to assess level of importance are topic specific but most often include, for areas of safety, effectiveness, and cost:

- risk of event occurring;
- the degree of harm associated with risk;
- the number of risks; the burden of the condition;
- burden untreated or treated with alternatives;
- the importance of the outcome (e.g. treatment prevents death vs relief of symptom);
- the degree of effect (e.g. relief of all, none, or some symptom, duration, etc.);
- value variation based on patient preference.

⁴ Based on GRADE recommendation: <u>http://www.gradeworkinggroup.org/FAQ/index.htm</u>

DIAGNOSTIC HEALTH TECHNOLOGY <u>Effectiveness / Accuracy</u>

Compared to current/alternative methods of diagnosis, does the scientific evidence confirm that use of the technology is more accurate? That is, does the use of the technology more accurately identify both those with the condition being evaluated and those without the condition being evaluated? Does the use of the technology result in better sensitivity and better specificity? Or do gains in sensitivity outweigh a reduction in specificity or vice versa such that on balance the diagnostic technology is thought to be more accurate than current diagnostic testing?

If the evidence does not show that use of the technology is more accurate, does the scientific evidence confirm that use of the technology is equally accurate – compared to currently available diagnostic testing? That is, does the use of the technology identify both those with the condition being evaluated and those without the condition being evaluated with accuracy equivalent to current diagnostic testing? Does the use of the technology result in equivalent sensitivity and specificity? Or are gains in sensitivity countered by loss of specificity or vice versa such that on balance the diagnostic technology is thought to be of equivalent accuracy to current diagnostic testing?

Or, finally compared to current/alternative methods of diagnosis, does the scientific evidence show that use of the technology is less accurate?

		Level of Confidence	Level of Confidence
Diagnosis	Diagnostic Outcome	Technology is Beneficial?*	Technology is Equivalent**
Degenerative Disc Disease	 More accurate Equally accurate Less Accurate Inconclusive 	 Confident[†] Not Confident 	☐ Confident [†] ☐ Not
Source of Pain	 More accurate Equally accurate Less Accurate Inconclusive 	 ☐ Confident[†] ☐ Not Confident 	☐ Confident [†] ☐ Not
Patients that will improve with lumbar fusion	 More accurate Equally accurate Less Accurate Inconclusive 	 ☐ Confident[†] ☐ Not Confident 	☐ Confident [†] ☐ Not
	 More accurate Equally accurate Less Accurate Inconclusive 	 ☐ Confident[†] ☐ Not Confident 	☐ Confident [†] ☐ Not
	 More accurate Equally accurate Less Accurate Inconclusive 	Confident [†] Not Confident	☐ Confident [†] ☐ Not

*Beneficial – Technology is more accurate **Equivalent – Technology is equivalent in accuracy [†]Confident – Generally supported by moderate or strong evidence

Does the scientific evidence confirm that use of the technology can safely and effectively replace other tests?

Test	Can the Technology Replace Other Test?	Level of Confidence Technology can replace other test?
MRI	Yes No	 ☐ Confident[†] ☐ Not Confident
Plain Radiographs	Yes No	 ☐ Confident[†] ☐ Not Confident
	Yes No	Confident [†] Not Confident
	Yes No	☐ Confident [†] ☐ Not Confident
	Yes No	 ☐ Confident[†] ☐ Not Confident

[†]Confident – Generally supported by moderate or strong evidence

Overall Efficacy: Does scientific evidence confirm that use of the technology results in better health outcomes than management without use of the technology?

Yes
No
Not

Not Studied/No Evidence

- Level of confidence that the evidence confirms that use of the technology results in better health outcomes?
 - Not Confident
 - Confident
 - Not applicable: The evidence does not show that the technology results in better health

outcomes.

DIAGNOSTIC HEALTH TECHNOLOGY

Safety

Morbidity

• Does scientific evidence confirm that use of the technology is free of or unlikely to produce significant morbidity? (either directly related to the diagnostic test or long term)?

Significant morbidity: Frequent adverse effect on health, but unlikely to result in lasting harm or be life-threatening, or;

Adverse effect on health that can result in lasting harm or can be life-threatening.

	Significant Morbidity	Level of Confidence
Morbid Outcome		Technology is Safe?*
Short term/direct	Morbidity Unlikely	
complication:	Morbidity Likely	\Box Confident [†]
Pain provocation	Inconclusive	Not Confident
complication		
Short term/direct	Morbidity Unlikely	
complication:	Morbidity Likely	Confident [†]
	Inconclusive	Not Confident
Short term/direct	Morbidity Unlikely	
complication:	Morbidity Likely	Confident [†]
	Inconclusive	Not Confident
Long term complication:	Morbidity Unlikely	
	Morbidity Likely	\Box Confident [†]
	Inconclusive	Not Confident
	Morbidity Unlikely	
	Morbidity Likely	Confident [†]
	Inconclusive	Not Confident
	Morbidity Unlikely	
	Morbidity Likely	\Box Confident [†]
	Inconclusive	Not Confident

*Safe – significant morbidity is unlikely

[†]Confident – Generally supported by moderate or strong evidence

• Does scientific evidence confirm that use of the technology is free of or unlikely to produce significant morbidity directly related to the diagnostic test?

Yes	-
No	
Not Studied/No Evidence	e

- In terms of short term morbidity, level of confidence that the evidence confirms use of the technology is safe:
 - Not confidentConfident

Mortality

- Does scientific evidence confirm that use of the technology is not likely to increase mortality?
 - Yes
 No
 - Not Studied / No or Inconclusive Evidence
- In terms of mortality, level of confidence that use of the evidence confirms the technology is safe:
 Not confident
 - Confident (Generally supported by moderate or strong evidence)

Overall

- Considering short and long term morbidity and mortality, does scientific evidence confirm that use of the technology is safe?
 - Yes
 - No
- Level of confidence that the evidence confirms that use of the technology is safe?

Not confident

Confident (Generally supported by moderate or strong evidence)

DIAGNOSTIC TEST TECHNOLOGY

Cost Impact

- Are independent cost analyses (cost benefit; cost effectiveness; or other cost analysis) identified?
 - Yes
 No

If Yes:

• Do the cost analyses show that use of the new technology will result in costs that are greater, equivalent or lower than management without use of the technology?

Greater
Equivalent
Lower

Not applicable: No independent cost analysis identified

<u>If No</u>:

- Does the evidence available to the committee indicate that use of the new technology will result in costs that are greater, equivalent or lower than management without use of the technology?
 - Short term costs (Cost of first year)
 - Greater Equivalent Lower Inconclusive
 - Long term costs (Costs beyond first year)
 - Greater
 - ____ Equivalent
 - Lower
 - Inconclusive

DIAGNOSTIC TEST TECHNOLOGY Benefit Evaluation

- Based on the current level of evidence regarding the technology's safety and effectiveness relative to currently available diagnostic methods, is use of the technology likely to have a net benefit, an equivalent benefit, less benefit or a net harm?
 - Net Benefit
 - Equivalent Benefit
 - Less Benefit
 - Net Harm
 - The available evidence does not permit a conclusion
- Based on the current level of evidence regarding the technology's cost impact relative to currently available diagnostic methods, is use of the technology likely to increase cost, result in equivalent cost or reduce cost?
 - Increase CostEquivalent CostLower Cost

Relative to currently available diagnostic methods, into which category does the evidence indicate use of the new technology will fall?

Less Benefit	Equivalent Benefit	Net Benefit
Increased Cost	Increased Cost	Increased Cost
Less Benefit	Equivalent Benefit	Net Benefit
Equivalent Cost	Equivalent Cost	Equivalent Cost
Less Benefit	Equivalent Benefit	Net Benefit
Reduced Cost	Reduced Cost	Reduced Cost

DIAGNOSTIC TEST TECHNOLOGY Coverage Determination

The HTCC has reviewed and considered the technology assessment and information provided by the administrator, reports and/or testimony from an advisory group, and submissions or comments from the public. The committee has given greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

- Based on the evidence that regarding the technology's safety, effectiveness, and cost-effectiveness, the use of the technology should be covered?
 - No. Evidence is insufficient to conclude that the health technology is safe, efficacious, and cost-effective or the evidence is sufficient to conclude that the health technology is unsafe, ineffectual, or not cost-effective

or

Yes. The evidence is sufficient to conclude that the health technology is safe, efficacious, and cost-effective for all indicated conditions; evidence is sufficient to conclude that

or

Yes, under certain conditions. Coverage is allowed with special conditions (e.g. population, conditions, timing, adjunct services, qualifications, etc.) because the evidence is sufficient to conclude that the health technology is safe, efficacious, and cost-effective only when:

This determination is consistent with the identified Medicare decisions and expert guidelines.

Based on the evidence, this determination is inconsistent with either the identified Medicare decisions or expert guidelines.